915 abstracts found.



Results filter

Development of novel imaging methods in mouse cancer models

Year:

Session type:

Kevin Brindle1

1University of Cambridge, Cambridge, UK


Introduction: Integration between oncology and palliative care

Year:

Session type:

Irene Higginson1

1King’s College London, London, UK


CRAd improve gene replication efficiency and cancer killing effect of E1-deleted adenovirus including killing gene in head and neck cancer cell line

Year:

Session type:

Seon-Hui Shim, Myung-Whun Sung

Cancer Research Institute, Seoul, Republic Of Korea


Interactions between RhoA-GTPase and cGMP/cAMP ignalling influence both the vascular disrupting and anti-angiogenic activities of combretastatin A-4-Phosphate

Year:

Session type:

Chryso Kanthou, Gillian Tozer

University of Sheffield, UK


Identification and characterisation of small molecule inhibitors of the atypical protein kinase C family (aPKC)

Year:

Session type:

Christelle Soudy1, Frederic Elustondo1, Christian Dillon1, Alex Boakes1, Carine Rosse2, Mark Linch2, Sven Kjaer2, Brenda Kostelecky2, Sarah Kaye1, Caroline Barton1, Aurore Lejeune1, Neil McDonald2, Peter Parker2, Caroline Foxton1, Tim Hammonds1, Lloyd Kelland1, Jon Roffey1

1Cancer Research Technology Discovery Laboratories, University College London, London, UK, 2London Research Institute, London, UK


Isolation of novel functional anti-cancer antibodies by phage display

Year:

Session type:

Sandrine Guillard, Steven Rust, David Lowne, Arthur Lewis, Ralph Minter, Lutz Jermutus

Medimmune, Cambridge, UK


The αvβ6 integrin – a novel target for antibody conjugated magnetic fluid hyperthermia in squamous cell carcinoma

Year:

Session type:

Daniel Marsh1, Heide Kogelberg1, Kim Vigor1, Paul Southern2, Berend Tolner1, Jag Chana3, Quentin Pankhurst2, Kerry Chester1

1Cancer Institute, UCL, London, UK, 2London Centre of Nanotechnology, London, UK, 3Royal Free Hospital, London, UK


An in vitro study of the pro‑apoptotic properties of green tea polyphenols in neoplastic cell lines

Year:

Session type:

Lakshman Nalluri1, David Jamieson3, Trevor Jackson3, Lisa Lee-Jones2

1Northumbria University, Newcastle-upon-Tyne, UK, 2Manchester Metropolitan University, Manchester, UK, 3Newcastle University, Newcastle-upon-Tyne, UK


Second-line treatment of ovarian carcinoma with pegylated liposomal doxorubicin (Caelyx®)

Year:

Session type:

Richard Turkington, Paula Scullin, Joanne Millar

Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK


Changes in Ca-125 relative to response following treatment with Pegylated Liposomal Doxorubicin (Caelyx®) in ovarian carcinoma

Year:

Session type:

Richard Turkington, Paula Scullin, Joanne Millar

Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK


The social impact of cancer on people of south Asian origin: staff and patient interview studies

Year:

Session type:

Naheed Hanif, Nimarta Dharni, Chris Bradley, Karl Atkin, Sangeeta Chattoo, Galina Velikova, Dan Stark, Penny Wright

Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford Teaching Hospitals Foundation Trust, UK


Antibodies: tools for research of and treatment of cancer

Year:

Session type:

Theresa Street

Cancer Research UK, London, UK


Glioma stem cell lines configured for patient-specific chemical genetic screens

Year:

Session type:

Steven Pollard1, Koichi Yoshikawa2, Ian Clarke2, Austin Smith1, Peter Dirks2

1Wellcome Trust Centre for Stem Cell Research, University of Cambridge, UK, 2The Hospital for Sick Children, University of Toronto, Canada


Regulation of tumor stroma angiogenesis by fibroblast cell-derived tetrahydrobiopterin

Year:

Session type:

Liye Chen1, Jihui Wang2, Jiliang Li1, Russell Leek1, Helen Turley1, David Kerr1, Adrian Harris1, Shijie Cai1

1University of Oxford, UK, 2College of Biology & Food Engineering, Dalian Polytechnic University, China


Molecular basis for maize as a risk factor for oesophageal cancer in a South African population via a prostaglandin E2 positive feedback mechanism

Year:

Session type:

Ryan C. Pink1, Tracey A. Bailey1, Jehu E. Iputo2, Alastair M. Sammon3, Anthony C. Woodman1

1Cranfield Health, Cranfield University, Bedfordshire, UK, 2Dept of Physiology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa, 3Dept of Surgery, Gloucestershire Royal Hospital, Gloucester, UK


Intravascular survival and proliferation determine brain metastasis formation

Year:

Session type:

W Shawn Carbonel, Olaf Ansorge, Ruth Muschel

University of Oxford, UK


The tumour suppressor protein LIMD1 specifically binds the HIF-prolyl hydroxylases and pVHL and represses HIF-1 mediated transcription

Year:

Session type:

Thomas M Webb1, Thilo Hagen1, Daniel E Foxler1, Maureen Mee1, Yunfeng Feng2, Gregory D Longmore2, Tyson V Sharp1

1University of Nottingham, UK, 2Washington University, St. Louis, USA


SAGE and MPSS profiling of stroma to identify regulators of prostate development and tumourigenesis

Year:

Session type:

Brigid Orr1, Griet Vanpoucke1, Oliver Grace1, Raymond Chan1, George Ashley1, Karin Williams2, Omar Franco2, Simon Hayward2, Richard Anderson1, Axel Thomson1

1Medical Research Council, Edinburgh, Lothian, UK, 2Vanderbilt University, Nashville, USA


Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib

Year:

Session type:

Feng-Ting Liu1, Samir G Agrawal1, Zanyar Movasaghi2, Peter B Wyatt3, Ihtesham U Rehman2, John G Gribben4, Adrian C Newland1, Li Jia1

1Institute of Cell and Molecular Science, Queen Mary University of London, London, UK, 2Department of Materials /IRC in Biomedical Materials, Queen Mary University of London, London, UK, 3School of Biological and Chemical Sciences, Queen Mary University of London, London, UK, 4Centre for Experimental Cancer Medicine, Institute of Cancer, Queen Mary University of London, London, UK


Wnt-11 promotes neuroendocrine-like differentiation, cell survival and migration in advanced prostate cancer

Year:

Session type:

Pinar Uysal-Onganer1, Soraya Diez1, Yoshiaki Kawano1, Siobhan Darrington1, Marjorie Walker1, Jonathan Waxman1, Robert Kypta2

1Imperial College London, London, UK, 2Centre for Cooperative Research in Biosciences, Bilbao, Spain


Inhibiting BCL-6

Year:

Session type:

Toni Hoffmann, Rob Ford, Paul Ko Ferrigno

Leeds Institute of Molecular Medicine, Leeds, West Yorkshire, UK


Identification of androgen receptor transcriptional complexes on distinct promoter targets

Year:

Session type:

Charlie Massie1, Falk Butter2, Andy Lynch1, Boris Adryan3, Nuno Barbosa-Morais1, Naomi Sharma1, Maxine Tran2, Matthias Mann1, David Neal1, Ian Mills1

1Cancer Research UK Cambridge Research Institute, University of Cambridge, UK, 2Max-Planck-Institute, Martinsried, Germany, 3Cambridge Systems Biology Centre, University of Cambridge, UK


CRT0066101, a small molecule inhibitor of protein kinase D, demonstrates in vitro and in vivo anticancer efficacy

Year:

Session type:

Stephen Jamieson, Azadeh Bagherzadeh, Mark Charles, Neil Jones, Florence Chan, Rachel Sutherland, Gregoire Pave, Julia Gilliatt, Kevin Stewart, Tim Hammonds, Caroline Foxton, Tony Raynham, Lloyd Kelland, Christopher Ireson

Cancer Research Technology Discovery Laboratories, University College London, London, UK


Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates Akt activation and potentiates mTOR blockade in breast cancer cells

Year:

Session type:

Matthew Roforth, Chalet Tan

Mercer University, Atlanta, USA


Characterisation of the Janus Kinase inhibitory activity of novel kinase inhibitor AT9283

Year:

Session type:

Jayne Curry, Kim Lewry, Caroline Richardson, Nicola Wallis, Andrew Woodhead

Astex Therapeutics, Cambridge, UK


Molecular mechanisms of T cell recruitment into renal cell carcinoma

Year:

Session type:

Kimberley Oldham1, Gregory Parsonage1, Michael Wallace3, Rupesh Bhatt3, Neeta Deshmukh4, Shalini Chaudri4, David Adams2, Steven Lee1

1Institute for Cancer Studies, University of Birmingham, Birmingham, UK, 2Institute of Biomedical Research, University of Birmingham, Birmingham, UK, 3Department of Urology, Queen Elizabeth Hospital, Birmingham, UK, 4Department of Pathology, Queen Elizabeth Hospital, Birmingham, UK


Ascorbate (Vitamin C) accelerates hydrogen-peroxide induced cell death in SK23 melanoma cells: vitamin C modulates the immune system?

Year:

Session type:

Rachel Haywood, Nick Sheppard, Carima Andrady

RAFT Institute, Middlesex, UK


Development of a novel, anti-angiogenic peptide derived from the C-terminal of MMP-inhibitor, TIMP-3

Year:

Session type:

Yung-Yi Chen, Claire Lewis, Michael Barker

University of Sheffield, Sheffield/South Yorkshire, UK


Use of nanomagnets to enhance monocyte delivery of gene therapy to tumours

Year:

Session type:

Munitta Muthana1, Simon Scott2, Craig Murdoch1, Neil Farrow3, Jon Dobson3, Claire Lewis1

1University of Sheffield, Sheffield, UK, 2University of Kent, Kent, UK, 3Keele University School of Medicine, Stoke on Trent, UK


Adenovirus 11: a potential oncolytic virus for pancreatic cancer therapy?

Year:

Session type:

Han Hsi Wong, Yaohe Wang, Nicholas Lemoine

Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, London, UK


Efficient lentiviral transduction of primary mouse T cells

Year:

Session type:

David Gilham1, Michael Lie-a-Ling2, Robert Hawkins1

1University of Manchester, Manchester, UK, 2Paterson Institute for Cancer Research, Manchester, UK


Increasing melanoma cell death using an inhibitor of protein disulphide isomerases to abrogate stress-survival responses

Year:

Session type:

Penny Lovat1, Marco Corazzari2, Jane Armstrong1, Shaun Martin1, Vittoria Pagliarini2, David Hill1, Anna Brown1, Mauro Piacentini2, Mark Birch-Machin1, Chris Redfern1

1Newcastle University, Newcastle upon Tyne, UK, 2L’Spallanzani National Institute for Infectious Disease, Rome, Italy


IgE antibody immunotherapy of solid tumours: A novel model targeting folate receptor with MOv18 IgE

Year:

Session type:

Sarah Rudman1, James Hunt2, Sophia Karagiannis3, James Spicer1, Hannah Gould2

1Division of Cancer studies, King's College London at Guy's Hospital, London, UK, 2Randall Institute, Division of Cell and Molecular Biophysics, King's College London at Guy's Hospital, London, UK, 3Division of Genetics and Molecular Medicine, King's College London at Guy's Hospital, London, UK


Setting up a multi-centre cancer biobank: key learning points

Year:

Session type:

Jane Rogan, Garry Ashton, Donna Johnstone, Noel Clarke

Manchester Cancer Research Centre, Manchester, UK


Patterns of bone metastases and bisphosphonate use in renal cancer patients in Leeds, UK

Year:

Session type:

Satinder Jagdev1, Katy Clarke1, Alex Newsham1, Kate Hayward1, Peter Selby2, Janet Brown2

1St James' Institute of Oncology, Leeds, UK, 2Cancer Research UK Academic Unit of Oncology, Leeds, UK


Bioavailability of four different sublingual formulations of fentanyl in healthy male volunteers: Phase I, randomised, open-label, crossover study

Year:

Session type:

Anders Pettersson1, Rob Derrick2, Andy Rust2

1Orexo AB, 754 50 Uppsala, Sweden, 2ProStrakan Group plc, Galashiels, TD1 1QH, UK


Immunotherapy of primary leukaemia by WT1-TCR engineered patient’s autologous T cells

Year:

Session type:

Shao-An Xue, Liquan Gao, Sharyn Tomas, Daniel Hart, John Zhao Xue, Emma Morris, Hans J Stauss

University College London, Royal Free Hospital, London, UK


Vandetanib shows potent efficacy against an EGFR dependent model of human lung cancer

Year:

Session type:

Rajesh Odedra, Sandra Brave, Gayle Marshall, Judith Anderton, Mark Hickinson, Robert W. Wilkinson, Simon Barry, Stephen R. Wedge, Anderson J. Ryan

Cancer and Infection Research Area, Astrazeneca, Macclesfield, Cheshire, UK


In vitro activity of the multitargeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response

Year:

Session type:

Michael A Batey, Jose LR Brito Brito, Helen Maitland, Hing Leung, Andrew Hall, Graham Jackson, David R Newell, Julie AE Irving

Northern Institute for Cancer Research, Newcastle University, Newcastle, UK


A novel small molecule inhibits cancer cell proliferation in vitro and in vivo via activation of the protein kinase AMPK

Year:

Session type:

Hakim Djeha1, Björn Eriksson2, Thomas Edlund2, Fiona McLaughlin1

1Antisoma Research Ltd, Welwyn Garden City, Herts, UK, 2Betagenon AB, Umeå, Sweden


Stimulation of VEGF-mediated angiogenesis and tumor growth by low concentrations of anti-angiogenic integrin inhibitors

Year:

Session type:

Andrew Reynolds7, Ian Hart1, Dylan Jones1, Mishal Salih1, Matt Jones2, Stephen Robinson1, Rita Silva1, Vassiliki Kostourou1, Garry Saunders3, Georges Da Violante4, Françoise Perron-Sierra5, Jim Norman2, Gordon Tucker6, Kairbaan Hodivala-Dilke1

1The Adhesion and Angiogenesis Lab, 2 Centre for Tumour Biology, Cancer Research UK Clinical Centre, Institute of Cancer, Barts and The London School Of Medicine and Dentistry, John Vane Science Centre,, London, UK, 2Integrin Cell Biology Laboratory, Beatson Institute for Cancer Research, Garscube Estate, Switchback Road,, Glasgow, UK, 3Cancer Research UK London Research Institute, Clare Hall Laboratories,, London, UK, 4Technologie Servier, 5 rue Bel Air, 45000 ,, Orléans, France, 5Institut de Recherches Servier (IdRS), Medicinal Chemistry Division, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France, 6Institut de Recherches Servier (IdRS), Cancer Drug Discovery Division, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France, 7Tumour Angiogenesis Group, Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK


Isoindolinone inhibitors of the MDM2-p53 protein-protein interaction: structure-activity studies

Year:

Session type:

Anna Watson, Eric Valeur, Bernard Golding, Roger Griffin, Claire Hutton, Jungfeng Liu, Xiaohong Lu, John Lunec, David Newell, Ian Hardcastle

Northern Institute for Cancer Research, Newcastle upon Tyne, UK


Therapeutic targeting of c-FLIP with antisense phosphorothioate oligonucleotides

Year:

Session type:

Andrew Logan, Timothy Wilson, Daniel Longley

Queen's University, Belfast, UK


Non-invasive imaging of Mitogenic Extracellular Kinase inhibition by PD0325901

Year:

Session type:

Julius Leyton1, Graham Smith1, Mark Lees1, Quange-de Nguyen1, Meg Perumal1, Franklin Aigbirhio2, Oksana Golovko2, Quimin He3, Paul Workman4, Eric O Aboagye1

1Imperial College London, London, UK, 2Wolfson Brain Imaging Center, Cambridge, UK, 3Huddinge University Hospital, Stockholm, Sweden, 4Institute of Cancer Research Institute, Sutton, Surrey, UK


Imaging tumour pH and carbonic anhydrase activity using magnetic resonance imaging

Year:

Session type:

Ferdia Gallagher1, Mikko Kettunen1, Sam Day1, Rebekah McLaughlin1, De-En Hu1, Jan Ardenkjær-Larsen4, Rene in ‘t Zandt5, Pernille Jensen5, Magnus Karlsson5, Klaes Golman5, Mathilde Lerche5, Kevin Brindle1

1Cancer Research UK, Cambridge Research Institute, Cambridge, UK, 2Department of Biochemistry, University of Cambridge, Cambridge, UK, 3Department of Radiology, University of Cambridge and Addenbrooke's Hospital, Cambridge, UK, 4GE Healthcare, Amersham, UK, 5Imagnia AB, Malmo, Sweden


Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo

Year:

Session type:

Tiernan Byrnes1, Thomas Barrick1, Anthony Bell1, Chris Clark2

1St. George's, Univeristy of London, London, UK, 2UCL Institute of Child Health, London, UK


Palliative external beam radiotherapy to the oesophagus – a single centre evaluation

Year:

Session type:

VS Kumar1, OS Din2, JC Wadsley1

1Dept of Clinical Oncology, Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, UK, 2Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, South Yorkshire, UK


Results of the radiotherapy comparison within BC2001 – a phase III randomised trial of standard versus reduced volume radiotherapy with or without synchronous chemotherapy in muscle invasive bladder cancer

Year:

Session type:

Robert Huddart1, Emma Hall2, Nicholas James3, Sayed Hussain3, Malcolm Crundwell4, Jean Tremlett5, Peter Jenkins6, Christine Rawlings7, Shaun Rogers2

1The Institute of Cancer Research, Clinical Academic Radiotherapy, Sutton, UK, 2The Institute of Cancer Research, Clincal Trials and Statistics Unit, Sutton, UK, 3University of Birmingham, CR-UK Institute for Cancer Studies, Birmingham, UK, 4Royal Devon and Exeter Hospital NHS Foundation Trust, Department of Urology, Exeter, UK, 5Sussex Cancer Centre, Department of Radiotherapy, Brighton, UK, 6Cheltenham General Hospital, Gloucestershire Oncology Centre, Cheltenham, UK, 7South Devon Healthcare Trust, Department of Radiotherapy, Torquay, UK


What is the role of tumour-associated bone marrow derived cells in the therapeutic response of tumours?

Year:

Session type:

Muhammad Babur, Majid Ali, Brian Telfer, Kaye Williams

University of Manchester, Manchester, UK


IMPORT LOW: Changing service delivery to optimise trial recruitment

Year:

Session type:

Mark Sydenham1, Judith Bliss1, Laura Ciurlionis3, Charlotte Coles2, Jo Haviland1, Jenny Titley1, John Yarnold1, IMPORT Trial Management Group4

1Institute of Cancer Research, Sutton, UK, 2Cambrodge University Hospitals NHS Foundation Trust, Cambridge, UK, 3Mount Vernon Hospital, Middlesex, UK, 4NHS, National, UK